
CBO Estimate of the Statutory Pay-As-You-Go Effects for Senate Amendment 2122 in the Nature of a Substitute to S. 3187, the Food and Drug Administration Safety and Innovation Act

| | By Fiscal Year, in Millions of Dollars | | | | | | | | | | | | 2012 - | 2012 - |
|--|--|----------|-----------|-----------|------------|------------|------------|------------|------------|------------|------------|------------|-------------|--------|
| | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2017 | 2022 | |
| NET DECREASE (-) IN THE DEFICIT | | | | | | | | | | | | | | |
| Statutory Pay-As-You-Go Impact | 0 | 0 | -1 | -5 | -19 | -46 | -66 | -44 | -72 | -71 | -39 | -71 | -363 | |
| Memorandum: | | | | | | | | | | | | | | |
| Changes in Outlays | 0 | 0 | -1 | -5 | -19 | -46 | -65 | -43 | -71 | -70 | -38 | -71 | -358 | |
| Changes in Revenues | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 5 | |

Source: Congressional Budget Office.

Notes: Components may not sum to totals because of rounding.

The bill would modify how the Food and Drug Administration regulates drugs and devices in a broad range of areas. Several provisions of the bill would affect when lower-priced drugs enter the market. Changing the timing of availability of lower-priced drugs affects spending in federal health programs that pay for prescription drugs and biological products. It would also reduce the costs of health insurance plans and thus reduce federal subsidies for health insurance purchased through an exchange.
